Get the Stockscreener App
75.36
0.03%
-0.02
After Hours:
75.36
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Bio Techne Corp stock is traded at $75.36, with a volume of 417.40K.
It is down -0.03% in the last 24 hours and up +6.53% over the past month.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
See More
Previous Close:
$75.38
Open:
$75.33
24h Volume:
417.40K
Relative Volume:
0.46
Market Cap:
$11.97B
Revenue:
$1.17B
Net Income/Loss:
$150.71M
P/E Ratio:
49.58
EPS:
1.52
Net Cash Flow:
$245.03M
1W Performance:
+5.72%
1M Performance:
+6.53%
6M Performance:
-4.12%
1Y Performance:
+19.39%
1-Day Range:
$74.51
$75.87
1-Week Range:
$71.90
$76.19
52-Week Range:
$61.16
$85.57
Bio Techne Corp Stock (TECH) Company Profile
Name
Bio Techne Corp
Sector
Industry
Phone
(612) 379-8854
Address
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
75.36 | 11.97B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-08-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-02-24 | Downgrade | Stifel | Buy → Hold |
| Dec-07-23 | Initiated | UBS | Buy |
| Aug-28-23 | Initiated | William Blair | Outperform |
| Jan-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Sep-15-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-08-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-23-21 | Upgrade | Stifel | Hold → Buy |
| Jan-25-21 | Reiterated | The Benchmark Company | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Jul-15-20 | Downgrade | Stephens | Overweight → Equal-Weight |
| May-27-20 | Downgrade | Stifel | Buy → Hold |
| May-14-20 | Initiated | The Benchmark Company | Buy |
| Jan-08-20 | Resumed | Stephens | Overweight |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-02-19 | Upgrade | Janney | Neutral → Buy |
| Jan-14-19 | Upgrade | Stephens | Equal-Weight → Overweight |
| Oct-31-18 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-17-18 | Initiated | Goldman | Neutral |
| Jun-15-18 | Initiated | Argus | Buy |
| Jul-13-17 | Initiated | Wells Fargo | Market Perform |
| Feb-09-17 | Initiated | Citigroup | Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Jan-21-15 | Reiterated | Robert W. Baird | Outperform |
| Sep-20-13 | Upgrade | Robert W. Baird | Neutral → Outperform |
View All
Bio Techne Corp Stock (TECH) Latest News
Bio-Techne Co. (NASDAQ:TECH) Shares Sold by Fred Alger Management LLC - MarketBeat
Bio-Techne Co. (NASDAQ:TECH) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
TECH (Bio-Techne) 3-Year Revenue Growth Rate : 7.80% (As of Sep. 2024) - GuruFocus.com
Techne (TECH) Up 2.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Dai ichi Life Insurance Company Ltd Cuts Stake in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Gene Editing Market Forecast Report 2024, with Profiles of Merck, GenScript, Revvity, Lonza, Precision BioSciences, Cellectis, AMSBIO, Synthego, Takara Bio, Bio-Techne, Reprocell and More - Yahoo Finance
BIO-TECHNE TO PRESENT AT THE CITI 2024 GLOBAL HEALTHCARE CONFERENCE – Company Announcement - Financial Times
Why Bio-Techne Corp (TECH) Is Set to Outperform the Market: Insi - GuruFocus.com
Charles Schwab Investment Management Inc. Has $113.02 Million Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne Co. (NASDAQ:TECH) Position Raised by Cerity Partners LLC - MarketBeat
Bio-Techne (TECH) Shares Cross Above 200 DMA - Nasdaq
Bio-Techne Co. (NASDAQ:TECH) Shares Sold by Eagle Asset Management Inc. - MarketBeat
Massachusetts Financial Services Co. MA Cuts Stock Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Mutual of America Capital Management LLC Purchases 8,852 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne (MEX:TECH) Dividend Payout Ratio : 0.19 (As of Sep. 2024) - GuruFocus.com
Bio-Techne (MEX:TECH) Debt-to-Equity : 0.19 (As of Sep. 2024) - GuruFocus.com
Are Wall Street Analysts Predicting Bio-Techne Stock Will Climb Or Sink? - Barchart
Are Wall Street Analysts Predicting Bio-Techne Stock Will Climb or Sink? - Inkl
Bio-Techne (BSP:T1CH34) Enterprise Value : R$70,339 Mil (As of Nov. 21, 2024) - GuruFocus.com
Brown Capital Management LLC Has $168.67 Million Stock Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne Co. (NASDAQ:TECH) Shares Acquired by Natixis Advisors LLC - MarketBeat
Thrivent Financial for Lutherans Sells 250,770 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne (STU:TE1) Enterprise Value : €10,153 Mil (As of Nov. 20, 2024) - GuruFocus.com
Bio-Techne Gears Up for Q1 Earnings Release: What's in the Cards? - MSN
Bio-Techne To Present At Stephens NASH 2024 Conference; Webcast At 12:00 PM ET - Nasdaq
BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH LEADER LIFE SCIENCES - Lelezard
Bio-Techne partners with Leader Life Sciences in GCC - Investing.com
Segall Bryant & Hamill LLC Has $38.20 Million Stock Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH - Quantisnow
Broadcrest Asset Management LLC Has $15.99 Million Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Royce & Associates LP Acquires 17,296 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
BIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO - Quantisnow
Geneva Capital Management LLC Has $88.27 Million Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Sumitomo Mitsui Trust Group Inc. Cuts Stock Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne To Present At UBS Global Healthcare Conference; Webcast At 12:30 PM ET - Nasdaq
Bio-Techne (NASDAQ:TECH) Raised to Buy at StockNews.com - MarketBeat
UPDATED: BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS - Quantisnow
BIO-TECHNE TO PRESENT AT INVESTOR CONFERENCES - Marketscreener.com
BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS - Quantisnow
Bio-Techne Co. (NASDAQ:TECH) is Montanaro Asset Management Ltd's 3rd Largest Position - MarketBeat
Ownership Capital B.V. Sells 208,493 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
When the Price of (TECH) Talks, People Listen - Stock Traders Daily
Bio-Techne Corporation: An Insight Into Its Market Position & Product Expansion in Diagnostics and Spatial Biology!Major Drivers - Smartkarma
Asset Management One Co. Ltd. Has $9.69 Million Stock Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
ScaleReady Announces multiple G-Rex® Grants have been awarded to leading investigators at the Baylor College of Medicine's Center for Cell and Gene Therapy - Quantisnow
Bio-Techne Co. (NASDAQ:TECH) Shares Sold by Van ECK Associates Corp - MarketBeat
There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings - Yahoo Finance
Ex-Dividend Reminder: Bio-Techne, Pfizer and Tompkins Financial - Nasdaq
BIO-TECHNE TO PRESENT AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 39TH ANNUAL MEETING - WV News
Beyond the Balance Sheet: What SWOT Reveals About Bio-Techne Corp (TECH) - Yahoo Finance
Bio-Techne (FRA:TE1) Change In Receivables : €-33 Mil (TTM As of Sep. 2024) - GuruFocus.com
Bio Techne Corp Stock (TECH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):